Mumbai-based clean-tech startup Exposome, founded in 2020 by Dr. Prerna Goradia, has raised $3 million in a Pre-Series A funding round to accelerate its expansion of regenerative filtration solutions for industrial and municipal air and water treatment. The round was led by Colossa WomenFirst Fund, with significant participation from Thermax Limited, a leader in energy and environment solutions, alongside co-investors including 3i Partners and Infinyte Club Angel Fund. Existing investors such as Rahul Rathi, Bhukhanvala Holdings, Excel Industries, and Spectrum Impact also contributed.
Exposome’s breakthrough lies in molecular filtration technologies designed to break free from traditional single-use filters. These regenerative filters target pollutants across sectors — industrial gases like CO₂, H₂S, NOₓ, and chemical contaminants in water such as PFAS and heavy metals — with a focus on sustainability, affordability, and ease of integration. The company’s products, globally patented and proudly “Made in India,” promise lower operational costs and carbon footprints by enabling multiple regeneration cycles instead of one-time use.
The funds will be deployed to scale manufacturing capacities, enhance R&D, and broaden Exposome’s footprint both in India and select international markets. The company is actively forging go-to-market partnerships across regions including Europe, North America, and East Asia — markets where industrial emissions regulations and demand for sustainable solutions are intensifying.
Dr. Prerna Goradia, Founder and CEO of Exposome, articulated the company’s vision succinctly: “Our mission is to bring deep-tech molecular filtration from India to the world. As regulatory and reputational pressures mount on industries to adopt sustainable practices, our scalable and cost-effective solutions are designed to meet this urgent demand.”
Ashu Suyash, CEO and Founder of Colossa Ventures, echoed this optimism, underscoring the strategic importance of women-led innovation: “Exposome’s regenerative technology is a game-changer in addressing persistent industrial pollutants such as PFAS, safeguarding water and health globally. Backing Dr. Prerna’s vision aligns with Colossa’s commitment to breakthrough clean-tech innovation.”
Editorial Perspective
Exposome’s fundraising milestone marks a significant inflection point in India’s clean-tech landscape, blending indigenous scientific innovation with global environmental imperatives. The company’s regenerative approach to filtration technology offers a compelling alternative to the waste-intensive, single-use filters that dominate the market, presenting a scalable model aligned with Net Zero ambitions.
As industries face tighter emissions standards and mounting scrutiny from regulators and consumers alike, the ability to retrofit sustainable solutions with lower capital and operational costs could drive accelerated adoption. Exposome’s technology, particularly in abating complex pollutants like PFAS—classified as ‘forever chemicals’ due to their persistence—positions it well ahead of many peers in addressing real-world environmental challenges.
Looking ahead, Exposome’s success will hinge on its capacity to establish strategic partnerships that bridge Indian innovation with global markets hungry for sustainable filtration technologies. The convergence of regulatory momentum, environmental urgency, and growing investor interest in cleantech startups creates a fertile ground for Exposome’s expansion. If it continues to refine its IP portfolio and scale manufacturing efficiently, the company could emerge as a benchmark for India’s ‘Make in India for the World’ ethos in advanced materials science.
If you need further assistance or have any corrections, please reach out to editor@thetimesmag.com.
